Cited 3 times in
Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현기 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2022-02-23T01:15:22Z | - |
dc.date.available | 2022-02-23T01:15:22Z | - |
dc.date.issued | 2021-12 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187603 | - |
dc.description.abstract | Purpose: The ability of the T-cell-inflamed gene expression profile (GEP) to predict clinical outcome in esophageal cancer (EC) is unknown. This retrospective observational study assessed the prognostic value of GEP and programmed death ligand 1 (PD-L1) expression in patients with EC treated in routine clinical practice. Methods: Tumor samples of 294 patients from three centers in Denmark, South Korea, and the United States, collected between 2005 and 2017, were included. T-cell-inflamed GEP score was defined as non-low or low using a cutoff of -1.54. A combined positive score (CPS) ≥10 was defined as PD-L1 expression positivity. Associations between overall survival (OS) and GEP status and PD-L1 expression were explored by Cox proportional hazards models adjusting for age, sex, histology, stage, and performance status. Results: Median age was 65 years; 63% of patients had adenocarcinoma (AC) and 37% had squamous cell carcinoma (SCC). Thirty-six percent of tumors were GEP non-low, with higher prevalence in AC (46%) than SCC (18%). Twenty-one percent were PD-L1-positive: 32% in South Korean samples versus 16% in non-Asian samples and 26% in SCC versus 18% in AC. GEP scores and PD-L1 CPS were weakly correlated (Spearman's R = 0.363). OS was not significantly associated with GEP status (non-low vs low; adjusted hazard ratio, 0.91 [95% CI, 0.69-1.19]) or PD-L1 expression status. Conclusion: Neither GEP nor PD-L1 expression was a prognostic marker in Asian and non-Asian patients with EC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | John Wiley & Sons Ltd. | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학교실) | - |
dc.contributor.googleauthor | Torben Steiniche | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Jeanette Baehr Georgsen | - |
dc.contributor.googleauthor | Morten Ladekarl | - |
dc.contributor.googleauthor | Marianne Nordsmark | - |
dc.contributor.googleauthor | Marie Louise Jespersen | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Hyunki Kim | - |
dc.contributor.googleauthor | Carly Fein | - |
dc.contributor.googleauthor | Laura H Tang | - |
dc.contributor.googleauthor | Ting Wu | - |
dc.contributor.googleauthor | Matthew J Marton | - |
dc.contributor.googleauthor | Senaka Peter | - |
dc.contributor.googleauthor | David P Kelsen | - |
dc.contributor.googleauthor | Geoffrey Ku | - |
dc.identifier.doi | 10.1002/cam4.4333 | - |
dc.contributor.localId | A01108 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00449 | - |
dc.identifier.eissn | 2045-7634 | - |
dc.identifier.pmid | 34693652 | - |
dc.subject.keyword | T-lymphocytes | - |
dc.subject.keyword | adenocarcinoma | - |
dc.subject.keyword | retrospective study | - |
dc.subject.keyword | squamous cell carcinoma | - |
dc.contributor.alternativeName | Kim, Hyunki | - |
dc.contributor.affiliatedAuthor | 김현기 | - |
dc.contributor.affiliatedAuthor | 김효송 | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 23 | - |
dc.citation.startPage | 8365 | - |
dc.citation.endPage | 8376 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, Vol.10(23) : 8365-8376, 2021-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.